Preventing Fever and Mortality with Fluoroquinolone Prophylaxis in Neutropenic Cancer Patients being Treated with Chemotherapy by Hall, Judson D.
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
8-15-2009
Preventing Fever and Mortality with
Fluoroquinolone Prophylaxis in Neutropenic
Cancer Patients being Treated with Chemotherapy
Judson D. Hall
Pacific University
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Hall, Judson D., "Preventing Fever and Mortality with Fluoroquinolone Prophylaxis in Neutropenic Cancer Patients being Treated
with Chemotherapy" (2009). School of Physician Assistant Studies. Paper 167.
Preventing Fever and Mortality with Fluoroquinolone Prophylaxis in
Neutropenic Cancer Patients being Treated with Chemotherapy
Abstract
Background: Neutropenia is the most common adverse effect of chemotherapy treatment but is often
necessary to destroy malignant disorders and neoplasms. As a patient undergoes most chemotherapeutic
regimens, myelosuppression occurs and reduces the patient’s ability to fight infection from harmful pathogens.
As neutropenia worsens, enteric flora are able to invade and proliferate, and opportunistic bacteria can cause
new infections. Antibiotics are available as focused and empiric treatment for these infections but are not
recommended for use in prevention. The use of antibiotics as prophylaxis in cancer patients with neutropenia
is controversial with published data supporting many conclusions.
Hypothesis: Current data available over the last decade is bringing consensus to prevention of fever and
mortality with the prophylactic use of fluoroquinolones in neutropenic cancer patients. It is hypothesized that
a review of this newer set of data will confirm the efficacy of fluoroquinolones as prevention of fever and
mortality in this patient population.
Study Design: A systematic review was performed to examine the pertinent published literature.
Methods: Inclusion keywords were determined for searching articles among multiple databases. Studies
eligible for inclusion into this review must be using a fluoroquinolone for prophylaxis in neutropenic cancer
patients receiving chemotherapy, be randomized controlled trials in the English language, and have a
publication date no earlier than the year 2000. Standard evidence based medicine critical review appraisals
were applied as well as scoring according to Jadad analysis to assess quality and validity of each study. Relative
risk, relative risk reduction, absolute risk reduction, number needed to treat, and a precision index were
calculated or included, as available. Qualitative weighting of these assessments was made during discussion
and conclusion.
Results: The review of literature and use of inclusion and exclusion criteria yielded six pertinent articles with
patient populations ranging from 70 to 1,565 individuals (Table I). The relative risk for fever or infection
ranged from 0.19 (p < 0.001) to 0.81(p = 0.02) and for mortality ranged from 0.0 (p =0.022) to 0.60 (95% CI
-0.05 to 0.005). Number needed to treat ranged from 3.1 to 22.7 for fever, and from 4.5 to 100 for mortality.
Jadad scoring ranged between 1 and 5 (out of 5) with two trials scoring ≤2 and 4 trials scoring ≥4.
Conclusion: After weighing the results of EBM reviews, Jadad scoring, and conclusive findings of these
studies, there is more evidence that prophylactic use of fluoroquinolones prevents fever and mortality in
treatment groups compared to control groups, with benefit increasing as severity of myelosuppression
increases. According to this systematic review, prophylactic fluoroquinolone use for prevention of fever is
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Abstract   
Background:  Neutropenia is the most common adverse effect of chemotherapy 
treatment but is often necessary to destroy malignant disorders and neoplasms.  As a 
patient undergoes most chemotherapeutic regimens, myelosuppression occurs and 
reduces the patient’s ability to fight infection from harmful pathogens.  As neutropenia 
worsens, enteric flora are able to invade and proliferate, and opportunistic bacteria can 
cause new infections.  Antibiotics are available as focused and empiric treatment for 
these infections but are not recommended for use in prevention.  The use of antibiotics as 
prophylaxis in cancer patients with neutropenia is controversial with published data 
supporting many conclusions. 
 
Hypothesis:  Current data available over the last decade is bringing consensus to 
prevention of fever and mortality with the prophylactic use of fluoroquinolones in 
neutropenic cancer patients.  It is hypothesized that a review of this newer set of data will 
confirm the efficacy of fluoroquinolones as prevention of fever and mortality in this 
patient population. 
 
Study Design:  A systematic review was performed to examine the pertinent published 
literature. 
 
Methods:  Inclusion keywords were determined for searching articles among multiple 
databases.  Studies eligible for inclusion into this review must be using a fluoroquinolone 
for prophylaxis in neutropenic cancer patients receiving chemotherapy, be randomized 
controlled trials in the English language, and have a publication date no earlier than the 
year 2000.  Standard evidence based medicine critical review appraisals were applied as 
well as scoring according to Jadad analysis to assess quality and validity of each study.  
Relative risk, relative risk reduction, absolute risk reduction, number needed to treat, and 
a precision index were calculated or included, as available.  Qualitative weighting of 
these assessments was made during discussion and conclusion. 
 
Results:  The review of literature and use of inclusion and exclusion criteria yielded six 
pertinent articles with patient populations ranging from 70 to 1,565 individuals (Table I).  
The relative risk for fever or infection ranged from 0.19 (p < 0.001) to 0.81(p = 0.02) and 
for mortality ranged from 0.0 (p =0.022) to 0.60 (95% CI -0.05 to 0.005).  Number 
needed to treat ranged from 3.1 to 22.7 for fever, and from 4.5 to 100 for mortality.  
Jadad scoring ranged between 1 and 5 (out of 5) with two trials scoring ≤2 and 4 trials 
scoring ≥4. 
 
Conclusion:  After weighing the results of EBM reviews, Jadad scoring, and conclusive 
findings of these studies, there is more evidence that prophylactic use of fluoroquinolones 
prevents fever and mortality in treatment groups compared to control groups, with benefit 
increasing as severity of myelosuppression increases.  According to this systematic 
review, prophylactic fluoroquinolone use for prevention of fever is recommended for all 
neutropenic cancer patients receiving chemotherapy. 
 
Keywords:  Neutropenia, fluoroquinolones, cancer, chemotherapy, antibiotic prophylaxis 
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 The treatment of hematological malignancies and solid tumor neoplasms with 
chemotherapeutic agents has been a significant part of the fight against cancer since 
World War I with the discovery of myelosuppression from mustard gas toxicity.  It was 
noted that mustard gas would suppress lymphoid and myeloid cell lines and that this may 
have been a vital aid in prolonging survival in lymphoma patients.  In the early 1940s, 
human clinical trials in the United States and Great Britain had begun to investigate 
treatment of lymphomas, leukemias, and solid tumors through lymphoid and myeloid 
suppression by nitrogen mustard.1  Since then, the science of chemotherapy as a 
treatment for cancers has exploded with complex pharmacologic developments that allow 
for destruction of cancer cells but often with narrow therapeutic indices.  It is a challenge 
to destroy the malignancy while keeping the patient’s own cells alive and functioning.  
Neutropenia is most often the result of chemotherapy and has become an unavoidable 
complication of cancer treatment today. 
 Myelosuppression resulting in neutropenia, anemia, and thrombocytopenia is 
common with many regimens of chemotherapy.  The nadir for white blood cells (WBC) 
occurs between 5 and 14 days following initiation of chemotherapy and mostly recovers 
by 7 to 21 days.  This will vary depending on the pharmacologic agent prescribed and the 
dosing regimen.2  Neutropenia, though expected, complicates treatment by lowering the 
patient’s ability to fight off microbial infection and is typically the dose limiting 
complication of chemotherapy administration.  Fever and severe infection are common, 
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and these immunocompromised patients are often admitted to the hospital and given 
empiric wide spectrum intravenous antibiotics, at significant cost, to fight these 
complications.  Morbidity and mortality may occur from bacterial sepsis and from 
localized infections such as pneumonia, until neutrophil counts improve and the patient is 
no longer immunocompromised. 
 Neutropenia is generally defined as an absolute neutrophil count (ANC) less than 
1500 cells/µL, with a significant decrease in ability to fight infection at less than 1000 
cells/µL, which is considered severe neutropenia.  At less than 500 cells/µL, life 
threatening infection is imminent from endogenous flora; particularly from enteric gram 
negative bacteria (GNB).2,3  Diagnosis of infection may be made by simple clinical 
objective findings, or through specific known focal site of infection that may or may not 
include microbial isolation through blood, sputum, or local cultures. 
 Febrile neutropenia (FN) varies in definition but typically is considered to be 
diagnostic in patients with neutropenia and temperature greater than 38°C for one hour or 
one episode at 38.3°C.  Infections in the neutropenic patient are most often bacterial in 
origin, but may also include viral and fungal etiology.  Common bacterial pathogens in 
FN are often from systemic seeding of endogenous enteric flora but also include P. 
aeruginosa or gram positive species.3,4 
 Prophylaxis with antibiotics for patients with expected neutropenia after 
chemotherapy is an area of medicine that comes with some disagreement.  The National 
Comprehensive Cancer Network (NCCN), the national authority for protocol in cancer 
care, has set guidelines that stratify three risk levels: low, intermediate, and high.  These 
risk levels are determined by the type of cancer and the treatment to be administered, and 
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have different levels of recommended prophylaxis.  According to the NCCN, low risk 
patients do not need bacterial prophylaxis, and intermediate and high risk patients may 
benefit from fluoroquinolone prophylaxis.5 
Fluoroquinolones are chosen for their wide spectrum coverage that includes GNB, 
simple dosing, and generally well tolerated adverse effects.  The fluoroquinolones, as a 
class, are bactericidal with a mechanism of action that inhibits replication of bacterial 
DNA through interference with DNA gyrase and topoisomerase IV.  Typical 
fluoroquinolones used in practice include ciprofloxacin, norfloxacin, levofloxacin, and 
moxifloxacin.  Organisms resistant to fluoroquinolones do exist, and include methicillin 
resistant Staph aureus, Pseudomonas, coagulase-negative Staphylococci, and 
Enterococci.6  Increase in resistance in this impressive antibacterial class is of concern 
when considering possibly unnecessary prophylaxis. 
Recent polling of practicing oncologists suggests that NCCN guidelines are not 
adhered to, and that clinical judgment and experience is often substituted when 
considering prophylaxis  in low risk category patients.  Of 1,207 oncologist respondents 
to a national survey in regards to antibiotic treatment and FN, a subset showed that 
fluoroquinolone prophylactic antibiotics are used in 45% of afebrile low risk patients.7  
While there are guidelines that are currently established and available, it would seem 
there is still either confusion, or disagreement on the evidence behind these rules. 
Much has been published on the use of prophylactic antibiotics in neutropenic 
cancer patients, in articles ranging from strict randomized controlled trials, to case 
studies, and reviews, over the past several decades.  Consensus is narrowing, especially 
with the publication of two large placebo controlled randomized trials in 2005 which 
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agreed that levofloxacin prophylaxis in afebrile neutropenic cancer patients was of 
significant benefit.8,9  In order to bring together the pertinent evidence available today 
and to answer a clinical question in regards to prevention of infection in neutropenic 
cancer patients, a systematic review was performed of randomized controlled trials that 
investigated the use of fluoroquinolones in this patient population.  Does fluoroquinolone 
prophylaxis prevent fever and mortality in neutropenic cancer patients being treated with 
chemotherapy?   
 
Methods 
Inclusion and Exclusion Criteria: 
 Trials included in this review were published randomized controlled trials that 
focused on the use of fluoroquinolones in the case of neutropenic cancer patients.  The 
included trials were not limited by age or demographic, with the only requirement of the 
selected population being human neutropenia in the setting of a cancer diagnosis.  
Selected trials met these criteria were in the English language with a publication date no 
earlier than the year 2000.  Excluded from this study were meta-analysis or systematic 
review articles, comment or anecdotal articles, and studies using fluoroquinolones as a 
second line intervention.   
 
Literature Search: 
 A search of the available literature was performed using MEDLINE-OvidSP, 
CINAHL, Web of Science, BIOSIS, and PubMed databases.  Search terms included 
neutropenia, fluoroquinolones, and antibiotic prophylaxis, and were limited to English 
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language, randomized controlled trials, human subjects, with a date range of year 2000 to 
the present.  The reference sections of eligible trials were also scrutinized for additional 
sources. 
 
Evidence Based Medicine (EBM) reviews: 
 Eligible studies were reviewed using JAMAevidence EBM review forms for 
therapy, and following Centre for Health Evidence at the University of Alberta Users’ 
Guides to Evidence-Based Practice.10  Relative risk (RR), relative risk reduction (RRR), 
absolute risk reduction (ARR), and number needed to treat (NNT) were calculated based 
on available data from the included studies.  Additional evaluation using the Jadad 
scoring method was implemented, with a numerical score of 0-5 measuring the quality of 
each article.11  Based on these reviews and scoring methods, conclusions were made in 
regards to the clinical question of effectiveness of fluoroquinolones in preventing fever 
and mortality in neutropenic cancer patients being treated with chemotherapy. 
 
Results 
 Search results after inclusion and exclusion criteria were examined, yielded 6 
articles to be reviewed (See Table I).8,9,12-15  In these studies, patient populations ranging 
from 70 to 1,565 individuals between 16 and 18 years of age, were randomized into 
treatment and control groups.  All were undergoing chemotherapy for a range of illnesses 
that included small-cell lung cancer (SCLC), solid tumors, acute leukemia, lymphoma, 
and other hematological malignancies.  Those receiving conditioning preparation for 
bone marrow transplant (BMT) were also included in several of the studies.  The 
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definition of neutropenia was consistently defined as ANC < 1000 cells/µL with the 
exception of the largest study and its follow-up analysis, which defined neutropenia as 
ANC < 500 cells/µL.8,12  Fever definition ranged from >38°C for one episode, with 
temperatures taken at different sites8,12 to >38.5°C for one episode.9 One study did not 
provide their definition of fever.15 
 Intervention with prophylactic fluoroquinolone antibiotics was used in each study 
with three articles using ciprofloxacin (dosing 500 twice daily to 750 twice daily)13-15 and 
two articles plus follow-up analysis using levofloxacin at 500mg daily.8,9,12  Two studies 
used additional antibiotic prophylaxis for improved gram positive coverage, including 
roxithromycin and colistin.13,14  Matching placebo comparison was used in all but one 
study, which compared fluoroquinolone prophylaxis to an aminoglycoside (neomycin).13  
Start times for the prophylactic regimen ranged from 1 to 3 days prior to chemotherapy 
initiation, to as late as day 14 days after initiation.  In one study it was unspecified at 
which time prophylactic therapy was initiated.13 
 The end point of intervention was determined by multiple methods, including: 
discontinuation at day 13 of cycle,14 for ANC ≥ 1.0 x 109/L or after a maximum of 30 
days,13 for ANC > 1.0 x 109/L,9,15 or after 7 consecutive days of treatment.8,12  Each study 
also had endpoints that included fever requiring empiric intravenous antibiotic use, with 
the exception of the SIGNIFICANT (Simple Investigation in Neutropenic Individuals of 
the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours) 
trial group, whose paper was published by Cullen et al, which required 7 days of 
consecutive treatment.8,12  In one study, data from the SIGNIFICANT trial group was 
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further analyzed to determine the effect of a fluoroquinolone on febrile episodes 
according to subgroups including cancer type, age, sex, and other factors.12 
 The EBM critical appraisal reviews and Jadad scoring of these articles reflect a 
range of quality that makes consensus on prevention in these patients difficult.  However, 
the larger trials are very well designed and documented, and are accordingly given more 
qualitative weight when making conclusions.  Quality assessment is performed using 
EBM criteria that monitors markers such as randomization, control of populations and 
accountability at outcome, methods of blinding, and similarity of treatment of groups (see 
Table II).  These items are essential in designing and reporting randomized controlled 
trials for publication and use by medical professionals.  Furthermore, calculations for 
EBM review and scoring according to Jadad method can be found in Table III for a 
numerical evaluation of the published results. 
The article written by Tjan-Heijnen et al was designed to determine reduction in 
FN through the prophylactic use of ciprofloxacin plus roxithromycin in comparison to 
matching placebo in SCLC patients.  It was concluded in the trial that a prophylactic 
regimen with ciprofloxacin and roxithromycin are effective at reducing episodes of FN in 
SCLC patients in comparison to placebo, and can be recommended for use.  The trial was 
randomized through minimization and followed a population of 161 adults through to 
completion.  All patients were accounted for at the end of the trial and there was no 
apparent cross-over during analysis.  Double-blinding was achieved by sealing the 
placebo versus treatment roster, and by providing a treatment pack distributed by a data 
center.  The treatment and control groups were similar, although limited information was 
given and no p values were assigned to determine if differences were significant or not.  
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Both groups were treated equally throughout the trial, with contingent plans for adverse 
effects or persistent fever.  Relative risk was 0.56 for fever with a p value of 0.007 and 
there were no deaths in the treatment group while 6 patients died in the control group (p = 
0.022).  Number needed to treat was calculated to be 5.3 for fever and 16.7 for death.  
Jadad scoring was determined to be 5 out of 5 on the basis of description of appropriate 
randomization, description of appropriate double-blinding, and all patients being 
accounted for through completion of their study.14 
 Prentice et al completed a study that would show prophylaxis against bacterial 
infection using ciprofloxacin plus colistin as the treatment intervention, and neomycin 
plus colistin as the comparison control group.  This article examined 150 adults with 
hematological malignancy and concluded that their treatment was effective in prevention 
of GNB infection.  A secondary finding was, that no significant resistant bacterial strains 
were isolated at a two year follow up.  This trial was unfortunately the weakest of those 
reviewed here as it did not adequately address important issues such as method of 
randomization, accountability of population at conclusion, nor the method of blinding.  It 
was also noted that 73% of patients in the treatment group developed fever and 90% in 
the control group developed fever.  These were the highest percentages of patients with 
fever of any of the studies presented here.  Treatment and control groups were however, 
treated equally and relative risk was determined to be 0.81 (p = 0.02) for fever and 0.37 
for death (p unknown, no CI provided).  Number needed to treat was calculated to be 5.9 
to prevent fever and 58.8 to prevent death.  Jadad scoring was determined to be 1 out of 5 
as the method of randomization was unknown, the population at conclusion was not well 
documented, and it is not certain whether patients were truly blinded for this study.13 
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 In the study by Nenova et al, the drugs used were of the fluoroquinolone class but 
different patients received different fluoroquinolones, with ciprofloxacin being the 
predominant regimen (48.8% of patients).  This study attempted to evaluate prophylaxis 
using fluoroquinolones initiated at the onset of neutropenia and the conclusion was 
reached that this does reduce risk for infection without significant difference in survival 
versus placebo.  This study also evaluated mortality at one month following 
chemotherapy initiation and found that the reduction of mortality was significant in the 
treatment group.  This trial consisted of 70 adults in an open prospective randomized 
trial.  The method of randomization is not specified and single-blinding of patients was 
achieved through undescribed placebo.  Follow up is complete with all patients receiving 
follow up for months 1 to 100 after chemotherapy.  In regards to similarity of groups, 
there may be differences in gender and type of malignancy between the treatment and 
control groups, but p values are not given to evaluate if this is statistically significant.  
Treatment of both test and control groups is equal.  Relative risk for infection (fever) and 
mortality in the first month were calculated as 0.19 and 0.21 respectively (p <0.001 and 
p< 0.01).  Number needed to treat for infection and fever is 3.1 and for death in the first 
month NNT is 4.5.  Jadad scoring is 2 out of 5 as the article does not adequately describe 
randomization and the trial is not double-blinded.15 
 The largest study of those reviewed, conducted by Cullen et al, includes 1,565 
patients with solid tumors and lymphomas.  The treatment group was given levofloxacin 
daily for seven consecutive days as an equal regimen for all patients in the group.  
Conclusion was made that levofloxacin reduces neutropenic fever, infection, and 
hospitalization.  The patients were adequately randomized using a computerized 
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minimization algorithm, and double-blinding was accomplished and described as 
matching placebo and by sealing of randomization codes.  All patients were accounted 
for at the end of follow-up and were described using a table.  The groups were similar 
and treated equally throughout the trial although no p values are given in Table 1 of the 
article.  For fever during the first chemotherapy cycle, the relative risk is 0.44 (95% CI 
0.28 to 0.68) and for overall severe infection or death, the relative risk is 0.50 (95% CI 
0.22 to 1.17).  In this study, number needed to treat to prevent fever during the first cycle 
was calculated to be 22.7, and for severe infection or death was found to be 100.  Jadad 
scoring of 5 out of 5 was given for superior documentation of methods including 
randomization, blinding, and accountability of all participants.8 
 In the GIMEMA (Gruppo Italiano Malattie Ematologiche dell’Adulto) trial by 
Bucaneve et al, 760 adults were randomized to either levofloxacin daily or an identical 
placebo, to  determine the prophylactic benefit in patients with acute leukemia, solid 
tumors, or lymphomas.  Prophylactic treatment was started 1 to 3 days prior to 
chemotherapy and continued until patients were no longer neutropenic.  Participants were 
randomized using a computer generated random number program and the study was 
described as double-blinded with description of placebo and comment on blinding of 
evaluators.  The patient population was complete and accounted for at the end of follow 
up as seen in the provided table, and both the treatment and control groups appear to be 
equal, although again there were no p  values provided to describe statistical significance 
of differences.  All participants were treated equally throughout the trial.  In regards to 
findings, relative risk was calculated to be 0.76 for fever (95% CI -0.26 to -0.14) and 0.60 
for death (95% CI -0.05 to 0.005).  The number needed to treat for successful prophylaxis 
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of fever was calculated to be 5 and for death was 50.  Jadad scoring of this study was 5 
out of 5 due to the excellent method of describing randomization, blinding, and 
documentation of patients at the conclusion of the study.9 
 This last trial was based on the data published in the SIGNIFICANT trial by 
Cullen et al, but was different, in that outcomes for specific subgroups were analyzed to 
determine whether or not the results would vary, when comparing the subgroups to the 
group as a whole.  The subgroups included cancer type, age, gender, cycle number, and 
other factors to be evaluated.  Cancer types included breast, testicular, SCLC, non-
Hodgkin’s lymphoma (NHL), and a category to represent other types.  The fresh 
examination of data concluded that, certain subgroups benefit more than others from 
bacterial prophylaxis using levofloxacin.  Patients in their first cycle of chemotherapy, or 
who have breast, testicular, and SCLC achieve the greatest benefit.  Original design and 
data collection of this study is the same as for the SIGNIFICANT trial.  Data to perform 
review calculations on the subgroups was not available, however, odds ratios with 95% 
confidence intervals were provided in the study.  For breast cancer the odds ratio was 
0.26 (95% CI 0.09 to 0.79).  The odds ratio for testicular cancer was found to be 0.39 
(95% CI 0.17 to 0.90) and for SCLC the odds ratio is 0.09 (95% CI 0.01 to 0.73).  The 
only subgroup that was found to possibly have disadvantage from prophylactic 
levofloxacin was the NHL subgroup with odds ratio 0.55 (95% CI 0.38 to 5.17).  Jadad 






 This systematic review was performed to answer a clinical question about 
prevention of fever and mortality in neutropenic cancer patients receiving chemotherapy, 
through the use of prophylactic flouroquinolones.  Current guidelines by the NCCN, last 
updated in 2008, state that low risk patients do not need bacterial prophylaxis, while 
intermediate and high risk patients may benefit from fluoroquinolone prophylaxis.5  
Although guidelines for bacterial prophylaxis in this group of patients are established, 
there is clearly a continuing need for clinical consistency in practice.  Recent evidence 
within the last decade has contradicted many prior studies from the 80s and 90s and also 
supported many studies from the same period.  Current guidelines state that not all cancer 
patients with expected neutropenia secondary to chemotherapy should be considered for 
antibiotic prophylaxis, but recent literature presents a challenge to these rules.  In each of 
the studies reviewed in this paper it has been concluded that prevention of fever with 
fluoroquinolone use in neutropenic cancer patients treated with chemotherapy is 
significantly effective as opposed to their respective control groups.  Two of the studies 
reviewed contain significant evidence that for their patient population and intervention, 
rates of mortality are also decreased in comparison to placebo.14,15  However, before a 
jump to prophylaxis for all neutropenic cancer patients is made, discussion must be 
conducted as to the validity and quality of each of these recently published trials. 
 The study by Prentice et al was not performed and documented appropriately 
according to established EBM review criteria (Table II) and to the Jadad score of 1 out of 
5.  At times it was difficult to determine how the patient populations were analyzed, and 
while conclusions were made, many of the standard methods of creating a double-blinded 
 17 
placebo controlled randomized clinical trial were neither adhered to, nor documented.  
The use of ciprofloxacin plus colistin in comparison to neomycin plus colistin did 
evidence reduction of febrile episodes in the patient population.  Analysis of mortality 
between the two populations was not performed.  Given the the overall quality of the 
study, it is difficult to rely on its conclusions when answering the clinical question, or to 
follow its recommendations when applying results to the patient population.  The quality 
and validity do not provide confidence in the end conclusion and if using this study by 
itself, it would not be recommended to use fluoroquinolone prophylaxis in neutropenic 
cancer patients. 
 In contrast, the trial by Tjan-Heijnen et al was not perfect either but was designed 
and documented well.  EBM review of the article and Jadad scoring (4 out of 5) gives 
confidence in the published results.  There was no confusion in the article as to patient 
populations, methods, follow up, or conclusions, and the authors provided effective 
evidence that prophylactic ciprofloxacin plus roxithromycin is useful in the prevention of 
fever and mortality in adult SCLC patients receiving chemotherapy.  This is one of two 
studies reviewed which supports the prophylactic use of fluoroquinolones in the 
reduction of mortality in neutropenic cancer patients.  They have shown that incidence of 
death is decreased in their patient population due to the intervention.  This is also the only 
study which has a patient population with a single specific form of cancer, a solid tumor 
type that demands extensive myelosuppressive chemotherapy.  The regimen used in this 
study was cyclophosphamide, doxorubicin, and etoposide (CDE), and the participants 
were grouped into intensive versus standard therapy, based on their disease status.  The 
advantage of using the intervention in the patients was seen most markedly in the 
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intensive therapy group, whose myelosuppression would have presumably been more 
substantial.  In current practice, oncologists have moved from toxic three drug regimens 
such as CDE, to two drug therapy such as carboplatin and etoposide, with resulting 
improved levels of myelosuppression.2  The data in this article, while well designed and 
valid, may not be representative outside a population of SCLC patients with severe 
disease receiving highly myelosuppressive chemotherapy.  In applying the conclusions to 
a wide population of patients undergoing chemotherapy, reservations should be apparent.  
It should be noted however, that conclusions can be drawn from this research that 
patients with impressive and significant levels of myelosuppression secondary to 
chemotherapy treatment, may benefit the greatest from fluoroquinolone prophylaxis.  
From the data presented in this article, it would be recommended that fluoroquinolone 
prophylaxis be used with a second agent that increases gram positive coverage to prevent 
fever and mortality in neutropenic cancer patients receiving chemotherapy, if severe 
levels of myelosuppression are predicted. 
 Nenova et al used multiple different fluoroquinolones as intervention in their trial 
versus placebo and produced a study that was moderately well designed and documented.  
Reviewing criteria for EBM quality and including Jadad scoring (2 out of 5) suggests 
weakness of this trial involving adults with hematological malignancies.  Produced at the 
Medical University, Plovdiv, Bulgaria, this study was the most difficult to come by but 
certainly meets inclusion and exclusion criteria and warrants integration into the review.  
The authors came to the conclusion that both fever and mortality are reduced through 
prophylactic use of fluoroquinolones in neutropenic cancer patients.  There are issues 
however, with this publication, most notably in the use of multiple different 
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fluoroquinolones without substantial documentation.  Definition of fever was also 
unspecified throughout the article, and when looking at endpoints of febrile episodes and 
assumed infections, this definition should have been included.  The trial was also an open 
trial, but it was indicated that patients were at least blinded through placebo.  Open trials 
lower confidence in outcomes due to likely bias in providers and evaluators.  
Nevertheless, open trials are still useful and should be considered in context with other 
available research.  There is also a question of whether or not possible differences in 
demographics of the two trial groups existed.  Both gender and type of malignancy may 
be statistically different, but p values were not calculated or given.  Despite some 
drawbacks to this trial, it does carry weight and it is recommended as partial evidence for 
fluoroquinolone prophylaxis of fever and mortality in neutropenic cancer patients 
receiving chemotherapy. 
 The remaining trials to be discussed are the most current evidence and the largest 
of all the trials included in this review.  They are also by far the best designed, 
implemented, and documented and therefore, carry the most weight in drawing final 
conclusions.  Both the SIGNIFICANT trial8,12 and the GIMEMA trial9 were published in 
the same issue of The New England Journal Of Medicine, as a direct challenge to existing 
thought on prophylaxis in neutropenic cancer patients.  They have successfully done just 
that by both arriving at the conclusion that prophylaxis with levofloxacin (a 
fluoroquinolone) in neutropenic cancer patients is effective and recommended.  Both 
studies also came to the conclusion that there is no significant difference in mortality 
between treatment and control goups.  The study by Cullen et al did also show that the 
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greatest effect in improving fever and mortality in their patient population was found in 
patients receiving a first cycle of chemotherapy as opposed to later cycles. 
 In Bucaneve et al, EBM review and Jadad scoring (5 out of 5) give great 
confidence in the outcome of the trial.  It should also be noted that NNT for prophylaxis 
of fever in this trial is the lowest of those reviewed which have a Jadad score >2.  A 
major difference between the GIMEMA trial and the SIGNIFICANT trial was that in the 
former, prophylaxis with levofloxacin was commenced prior to chemotherapy initiation 
and continued until neutropenia was resolved, or until infection required additional 
antibiotic therapy.  This likely changes the host flora prior to the onset of neutropenia 
which may prevent infection through decreased GNB load in the host.   The study by 
Cullen et al administered levofloxacin prophylaxis at days 5, 8, or 14 (depending on the 
number of days in the cycle and chemotherapy regimen to be given), and continued it for 
seven days in every treatment patient.  The other difference between these two trials is 
the definition of neutropenia, which is < 500 cells/µL in the trial by Cullen et al and 
<1000 cells/µL in the trial by Bucaneve et al.  This descrepancy however, doesn’t play a 
particularly important role in comparing these two studies, as Cullen et al did not use 
their definition for neutropenia in determining prophylactic dosing or administration.  
The two largest and most current trials reviewed here, give confidence to recommend the 
proposition that prevention of fever and mortality is improved with fluoroquinolone 
prophylaxis in neutropenic cancer patients being treated with chemotherapy.  
 A follow up analysis in the Journal of Clinical Oncology, used the 
SIGNIFICANT trial data and examined the benefit of prophylactic therapy with 
levofloxacin within specific subgroups.12  This article used the design and data collection 
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of the original SIGNIFICANT trial and therefore was reviewed similarly for EBM 
criteria and Jadad scoring, but came to more specific conclusions within the subgroups it 
analyzed.  It was found that breast cancer and especially testicular cancer and SCLC did 
benefit specifically from prophylaxis with levofloxacin, while some NHL patients may 
have been disadvantaged by this treatment.  These conclusions support previously 
discussed findings that as myelosuppression increases with more cytotoxic chemotherapy 
agents (such as etoposide used in testicular cancer and SCLC), that febrile episodes and 
mortality may be decreased with fluoroquinolone prophylaxis. 
 All statistical reviews are made more powerful through increasing the population 
size, and in this study  the limitation of the date range to this decade excluded many 
earlier trials from the review.  This decision was made to evaluate the most current 
information available, however, this precluded review of larger treatment populations.  
An increased number of studies may also have been included with search criteria 
inclusive of foreign languages and other types of trials.  Randomized controlled trials 
were used here as the best presented evidence with the most weight of all trial types, but 
conclusions can be effected by inclusion of other study types that may be significant.  
Further limitations can be seen in the restriction to antibiotic class and oral route.  Oral 
fluoroquinolones are the current standard for prophylaxis of neutropenic fever but other 
antibiotics and routes are also commonly used.  It is recommended that further study be 
completed to broaden search criteria to include valid trials that may have been 





 A systematic review was performed that allowed for inclusion of six studies that 
would provide insight into the clinical question of prevention.  Does fluoroquinolone 
prophylaxis prevent fever and mortality in neutropenic cancer patients being treated with 
chemotherapy?  All trials included in the study came to the conclusion that fever 
incidence is decreased with fluoroquinolone prophylaxis in this population.  
Improvement in mortality was found in two trials, but sufficient weight is not given to 
these results due to quality and validity of one of these trials.  After weighing results of 
EBM reviews, Jadad scoring, and conclusive findings of these studies, there is more 
evidence that prophylactic use of fluoroquinolones prevents fever and mortality in 
treatment groups compared to control groups, with the benefit increasing as severity of 
myelosuppression increases.  According to this systematic review, prophylactic 
fluoroquinolone use for prevention of fever is recommended for all neutropenic cancer 
patients receiving chemotherapy.  Increased inclusion criteria of future review or meta-
analysis studies is recommended to improve the data set included.  Further design and 
implementation of quality RCTs is as always, both helpful and recommended, and should 
focus on trends between severity of myelosuppression and severity of outcomes.
23 
 
Study Article Year Population Cancer type Intervention Comparison Start criteria End criteria Fever definition Neutropenia 
definition 
Tjan-Heijnen VCG, et 
al. 
Annals of Onc 






750mg po bid 
plus 
roxithromycin 
150mg po bid 
Matching 
placebo 
Day 4 of cycle Day 13 of cycle  
or neutropenic 
fever requiring IV 
antibiotics 
Oral ≥38.3°C or 
>38°C twice in 
12 hours 
WBC < 1.0 x 109/L 
Prentice HG, et al. 
Br. J. Haematol. 
2001 150 adults 
(≥18 yrs old) 
Haematologic
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Temp ≥38°C for 
at least 2 hours 
ANC < 1.0 x 109/L 
Nenova IS, et al. 
Folia Medica 
2001 70 adults 











Placebo At onset of 
neutropenia 
ANC > 1.0 x 109/L  




Unknown ANC < 1.0 x 109/L 
Cullen M, et al. 
(SIGNIFICANT trial) 
NEJM 
2005 1565 adults  
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Core >38°C ANC < 500 cells/µL 
Bucaneve G, et al. 
(GIMEMA trial) 
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1-3 days prior 
to 
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cells/µL 




or >38°C twice 
in 12 hours 
ANC < 1000 cells/µL 
Cullen M, et al. 
(SIGNIFICANT trial) 
JCO 
2007 1565 adults  
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Study Article Method of Randomization Population at conclusion Method of blinding Similarity of groups Treatment of 
Groups 
Tjan-Heijnen VCG, et 
al.  2001 






-Placebo with sealed 
roster, treatment pack 




(no p values given in 
table 1) 
Equal 
Prentice HG, et al. 
2001 
Br. J. Haematol. 
Randomized 
- Unknown 
Accounted for, not 
explained 
Unknown Similar  
-according to available 
data 
(no p values given in 
table 1) 
Equal 






-Survival rates of all 
patients reported for 
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Patients blinded by 
placebo.  Otherwise 
open study. 
Possible differences in 
sex and type of 
malignancy between 
treatment and control 
groups (no p values given 
in table 1) 
Equal 














(no p values given in 
table 1) 
Equal 
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-Table in prior publication 
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Score 
Tjan-Heijnen VCG, et 
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(Fever: p = 0.007  
Death: p = 0.022) 
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Prentice HG, et al. 
2001 











(Fever: p = 0.02) 
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Death in 1st 
month: 0.79 
Infection: 0.32 
Death in 1st month: 
0.22 
Infection: 3.1 
Death in 1st month: 
4.5 
Unknown 
(Infection: p < 0.001 
Death in 1st month:  
p < 0.01) 
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Severe infection or 
Death: 100 
First cycle- 
Fever: 0.28 to 0.68 
Severe infection or 
Death: 0.22 to 1.17 
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Fever: -0.26 to -0.14 
Death: -0.05 to 0.005 
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Fever during first 
cycle (Odds 
Ratios)- 
Breast CA: 0.26 





Data unavailable for 
calculation 
(NNT given for fever 
in first cycle) 
Breast CA: 32 




Breast CA: 0.09 to 0.79 
Testicular CA: 0.17 to 
0.90 
SCLC: 0.01 to 0.73 
NHL: 0.38 to 5.17 
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